Enbrel Solution For Injection 25Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Enbrel: Solution for injection (25mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Enbrel 25mg/0.5ml Soln for Inj

What is this Medicine?

ETANERCEPT (et a NER sept) is used for the treatment of rheumatoid arthritis in adults and children. The medicine is also used to treat psoriatic arthritis, ankylosing spondylitis, and psoriasis.

CVS Pharmacy Patient Statistics for Enbrel: Solution for injection(25mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Enbrel 25mg/0.5ml Solution for Injection

NDC: 584060455
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Rheumatoid Arthritis (JRA)/juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis

Storage Information
Refrigerate (between 36 and 46 degrees F)
Store in original package until time of use
Protect from light
Product must be used within 14 days after removal from refrigeration to room temperature (77 degrees F)
Do not freeze
Product stored at controlled room temperature should not be returned to a refrigerator
Enbrel 25mg/0.5ml Solution for Injection

Reported Side Effects for Enbrel 25mg/0.5ml Solution for Injection

Liver Infection Incidence:
<0.1%*
Severity: MODERATE
Onset: DELAYED
Convulsions Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Lupus-like Symptoms Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Inflamed Spinal Cord Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Pancytopenia Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Paresthesias Incidence:
<0.1%*
Severity: MILD
Onset: DELAYED
Aplastic Anemia Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Guillain-Barre Syndrome Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Heart Failure Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Inflamed Optic Nerve Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Itching Incidence:
1.0-5.0%*
Severity: MILD
Onset: RAPID
Skin Rash Incidence:
1.0-13.0%*
Severity: MILD
Onset: EARLY
Hives Incidence:
1.0-2.0%*
Severity: MILD
Onset: RAPID
Low White Blood Cells Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Fever Incidence:
2.0-3.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
3.0-16.0%*
Severity: MILD
Onset: EARLY
Antibody Formation Incidence:
6.0-15.0%*
Severity: MODERATE
Onset: DELAYED
Skin Redness Incidence:
7.0%*
Severity: MODERATE
Onset: EARLY
Injection Site Reaction Incidence:
15.0-43.0%*
Severity: MILD
Onset: RAPID
Sore Throat Incidence:
17.0-65.0%*
Severity: MILD
Onset: DELAYED
Sinus Infection Incidence:
17.0-65.0%*
Severity: MILD
Onset: DELAYED
Flu Incidence:
17.0-65.0%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
27.0-81.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Enbrel

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.